Mibefradil in the treatment of systemic hypertension: Comparative studies with other calcium antagonists

American Journal of Cardiology

Volumn 80, Issue 4 B, 1997, Pages

  Massie, Barry M ^a,b,c,d   Lacourcière, Yves ^a,b,c,d   Viskoper, Reuven ^a,b,c,d   Woittiez, Arend ^a,b,c,d   Kobrin, Isaac ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BARZILAI MEDICAL CENTER   (Israel)

^c TWENTEBORG HOSPITAL   (Netherlands)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; DILTIAZEM; MIBEFRADIL; NIFEDIPINE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADULT; AGED; AMLODIPINE; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; DILTIAZEM; DOUBLE-BLIND METHOD; EDEMA; FEMALE; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; LEG; MALE; MIBEFRADIL; MIDDLE AGED; NIFEDIPINE; TETRAHYDRONAPHTHALENES;

EID: 0030799742     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00567-5     Document Type: Article

References (14)

1. 2+ channels by Ro 40-5967. Circ Res. 75:1994;144-148.
2. Clozel J-P, Osterrieder W, Kleinbloesem C, Welker H, Schläppi B, Tudor R, Hefti F, Schmitt R, Eggers H. Ro 40-5967: a new non-dihydropyridine calcium antagonist. Cardiovasc Drug Rev. 9:1991;4-17.
3. Oparil S, Kobrin I, Abernethy D, Levine B, Reif M, Shepherd A. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. Am J Hypertens. 10:1997;735-742.
4. Bernink P, Prager G, Schelling A, Kobrin I. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Hypertension. 27:1996;426-432.
5. Bursztyn M, Kadr H, Tilvis R, Martina B, Oigman W, Talberg J, Kobrin I. Mibefradil, a novel calcium antagonist, in elderly hypertensives: favorable hemodynamics and pharmacokinetics. Am Heart J 1997; in press.
6. Carney S, Wing L, Ribeiro A, Kallwellis R, Zimlichman R, Viskoper R, Mion D Jr, Kobrin I. The addition of mibefradil to chronic hydrocholorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect. J Hum Hypertens. 11:1997;387-393.
7. Lacourcière Y, Poirer L, Lefebvre J, Archambault F, Dalle Ave S, Ward C. The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate-to-severe hypertensives with ambulatory hypertension. Am J Hypertens. 10:1997;189-196.
8. Massie B, Chrysant S, Jain A, Weir M, Weiss R, Kobrin I. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD. Clin Cardiol. 20:1997;562-568.
9. Viskoper R, Bernink P, Schelling A, Ribiero A, Kantola I, Wilkins M, Kobrin I. A randomized, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. J Hum Hypertens. 11:1997;459-466.
10. Kloner R. Nifedipine in ischemic heart disease. Circulation. 92:1995;1074-1078.
11. Furberg C, Psaty B, Meyer J. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 92:1995;1326-1331.
12. Gillum R, Makuc D, Feldman J. Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J. 121:1991;172-177.
13. Perski A, Ollson G, Landou C, de Faire U, Theorell T, Hamsten A. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J. 123:1992;609-616.
14. Kannel W, Kannel C, Paffenbarger R, Cupples A. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 113:1987;1489-1494.